<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-140 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-140</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-140</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific cell types showing susceptibility or resilience to Alzheimer's disease pathology, including quantitative measures of vulnerability and mechanistic explanations for differential vulnerability.</div>
                <p><strong>Paper ID:</strong> paper-1c55b1a84a53da83604c775a779bac404d9514ee</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/1c55b1a84a53da83604c775a779bac404d9514ee" target="_blank">iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases</a></p>
                <p><strong>Paper Venue:</strong> Neuron</p>
                <p><strong>Paper TL;DR:</strong> iMGLs were used to examine the effects of Aβ fibrils and brain-derived tau oligomers on AD-related gene expression and to interrogate mechanisms involved in synaptic pruning, and whole-transcriptome analysis demonstrates that they are highly similar to cultured adult and fetal human microglia.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e140.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e140.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific cell types showing susceptibility or resilience to Alzheimer's disease pathology, including quantitative measures of vulnerability and mechanistic explanations for differential vulnerability.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>iMGL / microglia</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>iPSC-derived microglia-like cells (iMGLs) / human microglia</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Human microglial-like cells generated from iPSCs that closely resemble fetal and adult human microglia at transcriptomic and functional levels; used here to model microglial interactions with Alzheimer's disease (AD) pathology (Aβ and tau), synaptic pruning, migration, cytokine secretion, and gene-expression responses to pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type</strong></td>
                            <td>microglia (iMGLs and primary fetal/adult microglia)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_description</strong></td>
                            <td>CNS-resident innate immune cells characterized here by expression of microglial markers (P2RY12, TREM2, TMEM119, PU.1, CX3CR1, MERTK, PROS1, P2ry12), low CD45 (CD45^low), ramified surveillance morphology, and functional properties including chemotaxis, calcium transients, cytokine secretion and phagocytosis of synaptosomes, fibrillar Aβ and brain-derived tau oligomers.</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_classification</strong></td>
                            <td>functionally implicated as both vulnerable (dysfunctional in AD) and active responders (capacity to clear pathology) — described as unable to fully clear plaques in disease but capable of phagocytosis when engaged</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region</strong></td>
                            <td>studied in vitro and after transplantation into mouse cortex and hippocampus (including migration along white matter tracts and clustering at amyloid plaques)</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>not explicitly staged in human disease; tested in models with established amyloid pathology (xenotransplanted Rag5xfAD mice with robust Aβ pathology) and in vitro exposure to Aβ fibrils and brain-derived tau oligomers</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_measure</strong></td>
                            <td>CD11b blockade reduced iMGL human synaptosome phagocytosis by 40.0% (***p<0.0001); MERTK inhibitor reduced synaptosome phagocytosis by 12.6% (*p<0.05); fAβ exposure increased expression of AD-GWAS genes including ABCA7 (5.79 ± 0.44-fold), CD33 (6.02 ± 0.41-fold), TREM2 (4.86 ± 0.50-fold), APOE (2.52 ± 0.19-fold); BDTOs increased CD2AP (4.62 ± 0.45-fold). iMGL purity by P2RY12/TREM2 co-expression >97.2% (n=5).</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_exposure</strong></td>
                            <td>fibrillar amyloid-β (fAβ), brain-derived tau oligomers (BDTOs), and synaptosomes (human synaptic material); in vivo exposure to Aβ plaques in transgenic AD mice after transplantation</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_of_susceptibility</strong></td>
                            <td>Microglial contribution to AD pathology is linked to incomplete clearance of Aβ plaques and to complement-mediated synaptic pruning; exposure to fAβ and BDTOs shifts microglial transcription toward upregulation of AD-GWAS and peripheral-myeloid-enriched genes (e.g., CD33, TYROBP) suggesting phenotype changes that may reduce effective clearance or increase inflammatory responses; loss of TGFβ signaling perturbs homeostatic microglial gene signature (including P2RY12, TGFBR1, CD33) potentially increasing susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_of_resilience</strong></td>
                            <td>Homeostatic programs maintained by TGFβ, neuronal signals (CD200, CX3CL1), and expression of homeostatic receptors (P2RY12, TMEM119) support surveillance and phagocytic functions; CD200/CX3CL1 exposure primes microglia to increase expression of phagocytosis/neuron-interaction genes (MS4A cluster, TREM2, TYROBP, CD33, ABCA7) which may enable more effective interaction with pathology; P2RY12-mediated chemotaxis and calcium signaling enable directed response to degenerating neurons (ADP).</td>
                        </tr>
                        <tr>
                            <td><strong>molecular_features</strong></td>
                            <td>High expression of microglial signature genes P2RY12, GPR34, C1Q, TREM2, TMEM119, PU.1, CX3CR1, MERTK, PROS1; AD-GWAS genes expressed and upregulated by pathology include ABCA7, CD33, TREM2, APOE, MS4A6A, PICALM, TYROBP; TGFβ-dependent maintenance of microglial signature (P2RY12, TGFBR1, CD33, EGR1, ETV5, APOE).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_other_cells</strong></td>
                            <td>Compared to monocyte-derived macrophages (MD-Mφ), iMGLs have lower CD45, lower magnitude synaptosome phagocytosis (iMGL phagocytosis less robust than MD-Mφ), and show a transcriptional program closer to primary microglia (fetal/adult) rather than peripheral myeloid cells; fAβ/BDTO exposure upregulated some genes normally enriched in peripheral myeloid cells (e.g., CD33, TYROBP, PICALM), suggesting pathology can shift microglia toward a peripheral-myeloid-like phenotype.</td>
                        </tr>
                        <tr>
                            <td><strong>methodology</strong></td>
                            <td>iPSC differentiation to iMGLs, RNA-seq and targeted qPCR (AD-GWAS qPCR), flow cytometry/FACS for marker expression, immunocytochemistry/IHC, in vitro phagocytosis assays with pHrodo-labeled fibrillar Aβ, BDTOs, and human synaptosomes, CD11b and MERTK pharmacologic blockade, cytokine multiplex assay (Mesoscale), transwell migration to ADP, calcium imaging (Fura-2), and in vivo xenotransplantation into MITRG and Rag5xfAD mice followed by histology.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases', 'publication_date_yy_mm': '2017-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e140.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e140.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific cell types showing susceptibility or resilience to Alzheimer's disease pathology, including quantitative measures of vulnerability and mechanistic explanations for differential vulnerability.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Human synaptosomes (synapses)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Human synaptosomes (isolated pre- and post-synaptic terminal fractions from human brain tissue)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Biochemically prepared synaptic terminal preparations used as a substrate to model synaptic pruning; here used to quantify microglial (iMGL) phagocytosis as a surrogate for synaptic vulnerability in AD-related processes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type</strong></td>
                            <td>synapses / synaptosomes (neuronal synaptic terminals)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_description</strong></td>
                            <td>Crude synaptosomal fraction isolated from human postmortem brain containing synaptic terminals and associated proteins; used as in vitro substrate to measure microglial phagocytosis (proxy for synaptic pruning).</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_classification</strong></td>
                            <td>vulnerable to microglia-mediated pruning in an AD-relevant context</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region</strong></td>
                            <td>derived from human brain tissue (region(s) not specified in detail in methods), used in vitro</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>not specified (substrates prepared from human tissue; microglial phagocytosis assessed in vitro rather than at a particular disease stage)</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_measure</strong></td>
                            <td>Blocking CD11b reduced iMGL phagocytosis of human synaptosomes by 40.0% (***p<0.0001); inhibition of MERTK reduced phagocytosis by 12.6% (*p<0.05). iMGL phagocytosis of synaptosomes was less robust compared to MD-Mφ (no absolute % given).</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_exposure</strong></td>
                            <td>assayed as targets for microglia-mediated engulfment (linked to complement/CR3 pathway implicated in AD synapse loss)</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_of_susceptibility</strong></td>
                            <td>Complement receptor 3 (CR3, CD11b/CD18)–mediated microglial phagocytosis is a primary pathway for synaptosome engulfment, implicating complement tagging of synapses leading to vulnerability; MERTK contributes only marginally.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_of_resilience</strong></td>
                            <td>Not directly described for synapses; by implication, blocking microglial CR3 (CD11b) reduces synaptic engulfment and could be protective against microglia-mediated synapse loss.</td>
                        </tr>
                        <tr>
                            <td><strong>molecular_features</strong></td>
                            <td>Engulfment is CR3 (CD11b/CD18)-dependent; MERTK plays a minor role. Complement component C1q and CR3 are expressed in iMGLs and are implicated in this pathway.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_other_cells</strong></td>
                            <td>iMGL-mediated synaptosome phagocytosis is reduced relative to MD-Mφ (monocyte-derived macrophages) in magnitude, suggesting microglia are more specialized/polarized toward homeostatic functions but still mediate complement-dependent synaptic pruning.</td>
                        </tr>
                        <tr>
                            <td><strong>methodology</strong></td>
                            <td>pHrodo-labeled human synaptosome phagocytosis assays measured by imaging flow cytometry (Amnis ImageStream) and internalization algorithms; pharmacologic blockade with additive-free anti-CD11b antibody and MERTK inhibitor (UNC569); statistical quantification of % change.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases', 'publication_date_yy_mm': '2017-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e140.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e140.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific cell types showing susceptibility or resilience to Alzheimer's disease pathology, including quantitative measures of vulnerability and mechanistic explanations for differential vulnerability.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MD-Mφ</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Monocyte-derived macrophages (MD-Mφ)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Peripheral blood monocytes differentiated in vitro with M-CSF into macrophages, used here as a comparator cell type to iMGLs to assess microglial-specific functions and relative phagocytic capacity towards AD-relevant substrates.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type</strong></td>
                            <td>monocyte-derived macrophages (MD-Mφ)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_description</strong></td>
                            <td>Macrophages generated from blood-derived monocytes by M-CSF treatment; express higher CD45 levels (CD45^hi) and exhibit robust phagocytic activity, serving as a peripheral myeloid comparator to microglia.</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_classification</strong></td>
                            <td>not directly classified for AD susceptibility in this paper; used as comparator showing greater phagocytic capacity for synaptosomes than microglia (iMGLs)</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region</strong></td>
                            <td>not brain-resident — peripheral myeloid cells derived from blood and studied in vitro; used as comparator to CNS microglia</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>not applicable / not specified</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_measure</strong></td>
                            <td>iMGL phagocytosis of human synaptosomes was less robust than MD-Mφ (no absolute fold given); some phagocytosis normalization to MD-Mφ used (exact normalization values not reported).</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_exposure</strong></td>
                            <td>used in vitro against same AD-relevant substrates (human synaptosomes, Aβ, BDTOs) for comparison; not reported as primary actors in brain-resident pathology in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_of_susceptibility</strong></td>
                            <td>Not specifically discussed as susceptible or resilient to AD pathology in this paper; peripheral-myeloid-enriched genes (e.g., CD33, TYROBP) are normally more enriched in these cells and are induced in microglia upon exposure to pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_of_resilience</strong></td>
                            <td>Not described.</td>
                        </tr>
                        <tr>
                            <td><strong>molecular_features</strong></td>
                            <td>Exhibit higher CD45 expression than iMGLs/microglia; used as reference for phagocytic potency. Some AD-GWAS genes are relatively enriched in peripheral myeloid cells at baseline.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_other_cells</strong></td>
                            <td>MD-Mφ have higher CD45 and more robust phagocytosis of human synaptosomes compared to iMGLs; iMGLs retain microglia-specific transcriptional signatures (P2RY12, TMEM119) that distinguish them from MD-Mφ.</td>
                        </tr>
                        <tr>
                            <td><strong>methodology</strong></td>
                            <td>Differentiation of CD14+ human monocytes with M-CSF for 5 days to generate MD-Mφ, followed by in vitro phagocytosis assays (pHrodo-labeled substrates) and flow/imaging cytometry for comparison to iMGLs.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases', 'publication_date_yy_mm': '2017-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Complement and microglia mediate early synapse loss in Alzheimer mouse models <em>(Rating: 2)</em></li>
                <li>Microglia development follows a unique yolk-sac derived lineage <em>(Rating: 1)</em></li>
                <li>TGFβ is required to maintain the microglia homeostatic signature <em>(Rating: 1)</em></li>
                <li>Asai et al. 2015 <em>(Rating: 1)</em></li>
                <li>Hong et al. 2016a <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>